Medivir AB invited to a conference call on the supporting clinical data from the completed dose escalation section of the phase 1b study with MIV-818, presented on September 16, 2021 at the European Society for Medical Oncology congress. The conference call will be held September 16, at to update on the study and the plan for the MIV-818 program. Medivir's lead candidate drug MIV-818 has the potential to become a liver-targeted, orally administered drug that can help patients with liver cancer. In April, it was announced that the overall results from the first part of the phase 1b study with MIV-818 were positive with a good safety and tolerability profile. The results from the completed dose escalation part of the phase 1b study will be presented as an e-poster (number 527P) at ESMO. The poster is presented by Dr. Debashi's Sarker, King's College, London. The overall safety profile was in line with expectations for this type of drug and patient population. A total of nine evaluable patients with various types of advanced cancer in the liver were enrolled. These were patients that had exhausted approved therapies prior to being enrolled. An important sign of efficacy was that four patients with hepatocellular carcinoma (HCC) showed stable disease in the liver over an extended period of time. Furthermore, liver biopsies from patients demonstrated delivery of MIV-818 to the liver, and a selective effect of MIV-818 on cancer cells across different types of cancer.